Media

Momenta CEO Craig Wheeler Highlights Auspicious Future for Biosimilars 2.23.2012

GPhA Statement on FDA Draft Guidance on Biosimilar Product Development 2.09.2012

GPhA Acclaims Hatch-Waxman as Model for Savings; Urges Shortened Exclusivity Period for Biogenerics 11.07.2011

GPhA Tells FDA that Science-Based Biogeneric Approval Process Is Needed To Assure Lower Costs for Patients 11.03.2010

GPhA/FDA Fall Tech Conference Highlights Coming Biosimilar Market 10.20.2010

White House Ignores Savings from Increasing Access to Generic Medicine 3.03.2010

GAO Report on Lack of Competition for Medicare Biotech Drugs Again Underscores Need for Congress to Act, GPhA Says 3.01.2010

GPhA Urges the White House and Congress to Heed Message of CCPM Health Care Reform Ad Campaign 12.17.2009

Senate HCR Bill Gratuitously Extends Biologic Monopolies: Lifts Brand Profits to New Heights At Consumer Expense 11.19.2009

GPhA Asks President Obama to Urge Congress to Strike Biogenerics from Health Care Reform if Provisions Are Not Substantially Altered 10.28.2009

New England Journal of Medicine Perspective Calls Upon President Obama to Encourage Congress to Adopt Exclusivity Periods for Biopharmaceuticals Similar to Those in Hatch-Waxman Act 10.15.2009

GPhA: Senator Hatch and Chairman Waxman Stress Important Role Generic Medicines Play in Strengthening Health Care System on 25th Anniversary of Hatch-Waxman Act 9.18.2009

GPhA: Obama Administration Says it Will Continue to Push for Seven Years of Market Exclusivity for Biogenerics 9.17.2009

GPhA Responds to House Energy and Commerce Committee Action on Biogenerics 7.31.2009

Generic Manufacturers Stated that Flawed Biogenerics Legislation Creates Ill-Advised Incentives for them to Produce Expensive Brand – Not Generic – Biotech Products 7.22.2009